CN115850249B - 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物 - Google Patents

具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物 Download PDF

Info

Publication number
CN115850249B
CN115850249B CN202210983564.6A CN202210983564A CN115850249B CN 115850249 B CN115850249 B CN 115850249B CN 202210983564 A CN202210983564 A CN 202210983564A CN 115850249 B CN115850249 B CN 115850249B
Authority
CN
China
Prior art keywords
substituted
group
unsubstituted
aromatic
substituent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210983564.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN115850249A (zh
Inventor
立花裕树
上原彰太
宇纳佑斗
中原健二
垰田善之
笠松幸司
山津维子
安藤茂
饭室敦弘
须藤贵弘
佐佐木道仁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hokkaido University NUC
Shionogi and Co Ltd
Original Assignee
Hokkaido University NUC
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hokkaido University NUC, Shionogi and Co Ltd filed Critical Hokkaido University NUC
Priority to CN202210983564.6A priority Critical patent/CN115850249B/zh
Publication of CN115850249A publication Critical patent/CN115850249A/zh
Application granted granted Critical
Publication of CN115850249B publication Critical patent/CN115850249B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202210983564.6A 2021-04-14 2022-02-17 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物 Active CN115850249B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210983564.6A CN115850249B (zh) 2021-04-14 2022-02-17 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP2021-068672 2021-04-14
JP2021068672 2021-04-14
JP2021105802 2021-06-25
JP2021-105802 2021-06-25
JP2021-153819 2021-09-22
JP2021153819 2021-09-22
CN202280000918.9A CN115038696A (zh) 2021-04-14 2022-02-17 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物
CN202210983564.6A CN115850249B (zh) 2021-04-14 2022-02-17 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物
PCT/JP2022/006495 WO2022138987A1 (ja) 2021-04-14 2022-02-17 ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202280000918.9A Division CN115038696A (zh) 2021-04-14 2022-02-17 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物

Publications (2)

Publication Number Publication Date
CN115850249A CN115850249A (zh) 2023-03-28
CN115850249B true CN115850249B (zh) 2024-07-02

Family

ID=82159864

Family Applications (6)

Application Number Title Priority Date Filing Date
CN202210983564.6A Active CN115850249B (zh) 2021-04-14 2022-02-17 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物
CN202410458057.XA Pending CN118359592A (zh) 2021-04-14 2022-02-17 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物
CN202311797713.0A Pending CN117820248A (zh) 2021-04-14 2022-02-17 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物
CN202310437344.8A Active CN116650498B (zh) 2021-04-14 2022-02-17 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物
CN202210742186.2A Active CN115073431B (zh) 2021-04-14 2022-02-17 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物
CN202280000918.9A Pending CN115038696A (zh) 2021-04-14 2022-02-17 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物

Family Applications After (5)

Application Number Title Priority Date Filing Date
CN202410458057.XA Pending CN118359592A (zh) 2021-04-14 2022-02-17 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物
CN202311797713.0A Pending CN117820248A (zh) 2021-04-14 2022-02-17 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物
CN202310437344.8A Active CN116650498B (zh) 2021-04-14 2022-02-17 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物
CN202210742186.2A Active CN115073431B (zh) 2021-04-14 2022-02-17 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物
CN202280000918.9A Pending CN115038696A (zh) 2021-04-14 2022-02-17 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物

Country Status (26)

Country Link
US (2) US12559474B2 (https=)
EP (2) EP4122926B1 (https=)
JP (3) JP7105430B1 (https=)
KR (2) KR20230159812A (https=)
CN (6) CN115850249B (https=)
AU (1) AU2022204775B2 (https=)
CA (1) CA3195272C (https=)
CL (1) CL2023003041A1 (https=)
CO (1) CO2022016323A2 (https=)
DK (1) DK4122926T3 (https=)
ES (1) ES3038833T3 (https=)
FI (1) FI4122926T3 (https=)
HR (1) HRP20250770T1 (https=)
HU (1) HUE072435T2 (https=)
IL (1) IL298794B2 (https=)
LT (1) LT4122926T (https=)
MX (1) MX2022014458A (https=)
PH (1) PH12022553603A1 (https=)
PL (1) PL4122926T3 (https=)
PT (1) PT4122926T (https=)
RS (1) RS66997B1 (https=)
SI (1) SI4122926T1 (https=)
SM (1) SMT202500268T1 (https=)
TW (1) TWI815396B (https=)
WO (2) WO2022138988A1 (https=)
ZA (1) ZA202212526B (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4122926T (lt) * 2021-04-14 2025-07-25 Shionogi & Co., Ltd. Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija
JP2024178473A (ja) * 2021-09-03 2024-12-25 塩野義製薬株式会社 ウイルス増殖阻害活性を有する二環性含窒素複素環誘導体およびそれらを含有する医薬組成物
WO2023054292A1 (ja) * 2021-09-28 2023-04-06 塩野義製薬株式会社 トリアジン誘導体を含有する医薬組成物
AU2022353486A1 (en) * 2021-09-28 2024-05-02 National University Corporation Hokkaido University Pharmaceutical composition containing triazine derivative
CN116782904A (zh) * 2021-09-28 2023-09-19 盐野义制药株式会社 含有三嗪衍生物的医药组合物
JP7261529B1 (ja) 2021-11-24 2023-04-20 塩野義製薬株式会社 ウイルス増殖阻害作用を有するトリアジン誘導体の製造方法
EP4289432A4 (en) * 2021-11-24 2025-01-15 Shionogi & Co., Ltd PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVES
CN116514734A (zh) * 2021-11-24 2023-08-01 盐野义制药株式会社 三嗪衍生物的制造方法和含有三嗪衍生物的口服给与的制剂
US20250025459A1 (en) * 2021-11-26 2025-01-23 Shionogi & Co., Ltd. Covid-19 treatment medicine characterized by combining 3cl protease inhibitor and covid-19 treatment drug
WO2023054732A2 (ja) * 2022-01-19 2023-04-06 塩野義製薬株式会社 新型コロナウイルス感染症治療用医薬
WO2023165459A1 (en) * 2022-03-01 2023-09-07 Fochon Biosciences , Ltd. Compounds as sars-cov-2 inhibitors
US11655240B1 (en) 2022-05-10 2023-05-23 Beijing Grand Johamu Pharmaceutical Company, Ltd. Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases
US20230302005A1 (en) * 2022-03-25 2023-09-28 Beijing Grand Johamu Pharmaceutical Company, Ltd. Active pharmaceutical ingredient, preparation method thereof, and pharmaceutical composition including the same
JP7624093B2 (ja) 2022-04-08 2025-01-29 塩野義製薬株式会社 ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物
CN114805314B (zh) * 2022-04-20 2023-12-15 杭州国瑞生物科技有限公司 一种恩赛特韦的合成方法
CN117126141A (zh) * 2022-05-25 2023-11-28 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物及其制备和应用
WO2023227117A1 (zh) * 2022-05-27 2023-11-30 广州国家实验室 3c样蛋白酶抑制剂
WO2023226679A1 (zh) * 2022-05-27 2023-11-30 广州国家实验室 3c样蛋白酶抑制剂
CN117159556A (zh) * 2022-05-27 2023-12-05 北京远大九和药业有限公司 一种药物组合物及其制备方法和用途
CN117122601A (zh) * 2022-05-27 2023-11-28 北京远大九和药业有限公司 包含化合物与富马酸的结晶形式的药物组合物及其制备方法和用途
WO2023227118A1 (zh) * 2022-05-27 2023-11-30 广州国家实验室 3c样蛋白酶抑制剂
CN117186077A (zh) * 2022-06-01 2023-12-08 陕西盘龙药业集团股份有限公司 一种3-三唑基甲基-1,3,5-三嗪-2,4-二酮类化合物及其制备方法和应用
WO2024009120A1 (en) * 2022-07-08 2024-01-11 Ascletis Bioscience Co., Ltd. Triazine derivatives and methods of use thereof
CN115490681B (zh) * 2022-07-08 2023-04-18 歌礼生物科技（杭州）有限公司 三嗪衍生物
CN117402144B (zh) * 2022-07-14 2026-03-06 广东东阳光药业股份有限公司 一种3cl蛋白酶抑制剂的制备方法
CN117402185A (zh) * 2022-07-14 2024-01-16 广东东阳光药业股份有限公司 三嗪类化合物及其在药物中的应用
CN114989048B (zh) * 2022-07-19 2023-05-23 郑州大学 环丁-1-烯胺类化合物及其制备方法和在抗ⅱ型登革病毒药物中的应用
CN114933594A (zh) * 2022-07-20 2022-08-23 北京科翔中升医药科技有限公司 一种氟代三嗪类化合物、药物组合物及用途
CN117466873A (zh) * 2022-07-29 2024-01-30 广东东阳光药业股份有限公司 嘧啶类化合物及其在药物中的应用
CN115260167B (zh) * 2022-08-01 2025-01-21 陕西盘龙药业集团股份有限公司 一种3-四唑基甲基-1,3,5-三嗪-2,4-二酮类化合物及其制备方法和应用
CN115109042B (zh) * 2022-08-30 2023-05-26 北京科翔中升医药科技有限公司 三嗪类化合物或其可药用的盐、药物组合物和用途
CN115504968B (zh) * 2022-11-21 2023-04-18 歌礼生物科技（杭州）有限公司 三嗪衍生物
CN115819407A (zh) * 2022-12-13 2023-03-21 浙江乐普药业股份有限公司 一种Ensitrelvir类似物及其制备方法和抗新冠用途
CN115785080B (zh) * 2022-12-16 2024-10-11 陕西盘龙药业集团股份有限公司 一种尿嘧啶母核类化合物及其制备方法和应用
IL321635A (en) 2022-12-23 2025-08-01 Meiji Seika Pharma Co Ltd The aftermath of avermectin
CN115991700B (zh) * 2023-01-20 2025-07-18 厦门蔚扬药业有限公司 一种含硒的三嗪衍生物及其制备方法和用途
CN116621817B (zh) * 2023-07-20 2023-09-29 爱斯特（成都）生物制药股份有限公司 一种富马酸恩赛特韦的晶型及其制备方法、药物组合物和用途
WO2025058977A1 (en) * 2023-09-11 2025-03-20 Vir Biotechnology, Inc. Modulators of coronavirus 3c-like protease and uses thereof
AU2024309726A1 (en) * 2023-10-05 2026-04-16 Shionogi & Co., Ltd. Preparation containing uracil derivative
AU2024307335A1 (en) * 2023-10-05 2026-04-16 Shionogi & Co., Ltd. Pharmaceutical composition containing uracil derivative
WO2025125695A2 (en) 2024-12-17 2025-06-19 Medchemica Consultancy Ltd Chemical compoundsid50000167790940 p. doc 2025-05-07 filing no.:19

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013089212A1 (ja) * 2011-12-15 2013-06-20 塩野義製薬株式会社 置換トリアジン誘導体およびそれらを含有する医薬組成物

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2631625B1 (fr) * 1988-05-17 1992-10-16 Synthelabo Derives de phenyl-6 piperazinylalkyl-3 1h,3h-pyrimidinedione-2,4, leur preparation et leur application en therapeutique
EP0442473B1 (en) 1990-02-15 1998-08-19 Takeda Chemical Industries, Ltd. Pyrimidinedione derivatives, their production and use
JP3032844B2 (ja) * 1990-02-15 2000-04-17 武田薬品工業株式会社 ピリミジンジオン誘導体
WO2001055119A2 (en) * 2000-01-25 2001-08-02 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US7449473B2 (en) * 2003-10-31 2008-11-11 Cv Therapeutics, Inc. Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists
US7462594B2 (en) * 2003-12-31 2008-12-09 Taigen Biotechnology Co., Ltd. Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases
CN1926128A (zh) * 2004-03-15 2007-03-07 武田药品工业株式会社 二肽基肽酶抑制剂
UA85871C2 (uk) * 2004-03-15 2009-03-10 Такеда Фармасьютікал Компані Лімітед Інгібітори дипептидилпептидази
KR20080006564A (ko) 2005-03-24 2008-01-16 얀센 파마슈티카 엔.브이. 프로키네티신 1 수용체 길항제
WO2007007161A2 (en) * 2005-07-08 2007-01-18 Orchid Research Laboratories Limited Novel bio-active derivatives
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN100502868C (zh) * 2005-11-18 2009-06-24 北京大学 非肽类sars冠状病毒3cl蛋白酶抑制剂及其用途
WO2007079163A2 (en) * 2005-12-29 2007-07-12 Janssen Pharmaceutica N.V. Prokineticin 1 receptor antagonists
WO2007112368A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
JP5140154B2 (ja) * 2007-06-27 2013-02-06 アストラゼネカ・アクチエボラーグ ピラジノン誘導体および肺疾患の処置におけるそれらの使用
JP2011502154A (ja) * 2007-10-30 2011-01-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アミノヘテロアリールを含むプロキネチシン１受容体拮抗物質連邦政府支援研究又は開発に関する陳述下に記述される本発明の研究及び開発は、連邦政府の支援によるものではない。
PL2399910T3 (pl) 2009-02-13 2014-09-30 Shionogi & Co Pochodne triazyny jako antagoniści receptora p2x3 i/albo p2x2/3 i kompozycja farmaceutyczna zawierająca je
WO2012006004A1 (en) 2010-06-28 2012-01-12 Janssen Pharmaceutica Nv Prokineticin 1 receptor antagonists for the treatment of pain
EP2585068A1 (en) * 2010-06-28 2013-05-01 Janssen Pharmaceutica, N.V. Prokineticin 1 receptor antagonists for the treatment of pain
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
CN103153968B (zh) 2010-08-10 2016-02-03 盐野义制药株式会社 三唑衍生物及含有其的具有镇痛作用的药物组合物
JP6075621B2 (ja) 2010-08-10 2017-02-08 塩野義製薬株式会社 新規複素環誘導体およびそれらを含有する医薬組成物
CN102807568B (zh) * 2011-05-31 2015-11-25 正大天晴药业集团股份有限公司 噻二唑衍生物类dpp-iv抑制剂
CN103159665B (zh) * 2011-12-09 2017-01-25 天津市国际生物医药联合研究院 对sars冠状病毒主蛋白酶具有抑制作用的靛红‑5‑酰胺类抑制剂
WO2013118855A1 (ja) 2012-02-09 2013-08-15 塩野義製薬株式会社 複素環および炭素環誘導体
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
JP6403172B2 (ja) * 2013-10-25 2018-10-10 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ピリジンのケトン誘導体、それらの製造方法、およびそれらの医薬適用
CN104109147B (zh) * 2014-06-21 2016-10-05 安徽省逸欣铭医药科技有限公司 羟基脒基苯类衍生物及其制备方法和医药用途
US10183949B2 (en) * 2014-08-29 2019-01-22 The University Of Tokyo Pyrimidinone derivative having autotaxin-inhibitory activity
JP2016079168A (ja) * 2014-10-17 2016-05-16 塩野義製薬株式会社 ９員縮合環誘導体
TWI700284B (zh) * 2015-05-29 2020-08-01 日商塩野義製藥股份有限公司 具有ｈｉｖ複製抑制作用之含氮３環性衍生物
TW201817714A (zh) * 2016-08-30 2018-05-16 英商葛蘭素史密斯克藍智慧財產權有限公司 抑制3c及3cl蛋白酶之化合物及其使用方法
JP7116356B2 (ja) * 2017-11-28 2022-08-10 日産化学株式会社 トリアジン－２，４－ジオン誘導体及びその製造方法
PH12021552872A1 (en) 2020-04-05 2022-03-21 Pfizer Compounds and methods for the treatment of covid-19
CN112516122A (zh) * 2020-04-21 2021-03-19 洪楠方 苏拉明在制备预防或治疗冠状病毒相关疾病药物中的用途
CA3188794A1 (en) * 2020-08-11 2022-02-17 William FITZSIMMONS Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
EP4282420A4 (en) * 2021-01-20 2024-11-27 National University Corporation Hokkaido University ANTIVIRAL AGENT
EP4313097A4 (en) * 2021-03-29 2025-03-19 Shireen Nature Company for General Trading, Ltd. Willow extract and its use in treating coronavirus infection, inflammation, and associated medical conditions
LT4122926T (lt) * 2021-04-14 2025-07-25 Shionogi & Co., Ltd. Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija
CN113801097B (zh) 2021-09-27 2022-11-22 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物、其制备方法及用途
CN113735838B (zh) 2021-09-27 2022-07-08 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物、其制备方法及用途
CN113620888B (zh) 2021-09-27 2023-06-06 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物及其制备方法和应用
CN113666914B (zh) 2021-09-27 2022-06-07 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物及其制备方法和用途
CN113773300B (zh) 2021-09-27 2022-10-11 成都施贝康生物医药科技有限公司 磺酰胺类化合物、其制备方法及用途
WO2023054292A1 (ja) 2021-09-28 2023-04-06 塩野義製薬株式会社 トリアジン誘導体を含有する医薬組成物
AU2022353486A1 (en) * 2021-09-28 2024-05-02 National University Corporation Hokkaido University Pharmaceutical composition containing triazine derivative
CN116782904A (zh) * 2021-09-28 2023-09-19 盐野义制药株式会社 含有三嗪衍生物的医药组合物
EP4289432A4 (en) * 2021-11-24 2025-01-15 Shionogi & Co., Ltd PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVES
WO2023054732A2 (ja) * 2022-01-19 2023-04-06 塩野義製薬株式会社 新型コロナウイルス感染症治療用医薬
CN117069706A (zh) * 2022-05-10 2023-11-17 北京远大九和药业有限公司 一种化合物的结晶形式及其制备方法和用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013089212A1 (ja) * 2011-12-15 2013-06-20 塩野義製薬株式会社 置換トリアジン誘導体およびそれらを含有する医薬組成物

Also Published As

Publication number Publication date
EP4122926A4 (en) 2023-08-30
US12559474B2 (en) 2026-02-24
US11814368B2 (en) 2023-11-14
WO2022138988A1 (ja) 2022-06-30
DK4122926T3 (da) 2025-06-30
HRP20250770T1 (hr) 2025-08-29
SI4122926T1 (sl) 2025-09-30
RS66997B1 (sr) 2025-08-29
CN117820248A (zh) 2024-04-05
FI4122926T3 (fi) 2025-07-23
SMT202500268T1 (it) 2025-09-12
JPWO2022138988A1 (https=) 2022-06-30
CN118359592A (zh) 2024-07-19
HUE072435T2 (hu) 2025-11-28
JP7530596B2 (ja) 2024-08-08
EP4400502A3 (en) 2025-01-01
PH12022553603A1 (en) 2024-03-04
KR20220142999A (ko) 2022-10-24
CN115038696A (zh) 2022-09-09
EP4122926A1 (en) 2023-01-25
KR102494188B1 (ko) 2023-01-31
IL298794B1 (en) 2024-02-01
CN115073431A (zh) 2022-09-20
WO2022138987A1 (ja) 2022-06-30
CA3195272C (en) 2024-02-13
CO2022016323A2 (es) 2023-02-16
JP2024153693A (ja) 2024-10-29
CN115073431B (zh) 2023-09-05
EP4122926B1 (en) 2025-06-04
JP7738869B2 (ja) 2025-09-16
LT4122926T (lt) 2025-07-25
AU2022204775B2 (en) 2023-03-30
CA3195272A1 (en) 2022-06-30
AU2022204775A1 (en) 2022-12-08
KR20230159812A (ko) 2023-11-22
IL298794B2 (en) 2024-06-01
MX2022014458A (es) 2023-02-27
TWI815396B (zh) 2023-09-11
US20230128162A1 (en) 2023-04-27
IL298794A (en) 2023-02-01
TW202302571A (zh) 2023-01-16
ZA202212526B (en) 2023-05-31
CL2023003041A1 (es) 2024-03-15
CN115850249A (zh) 2023-03-28
JP7105430B1 (ja) 2022-07-25
CN116650498A (zh) 2023-08-29
US20230212154A1 (en) 2023-07-06
PL4122926T3 (pl) 2025-09-29
CN116650498B (zh) 2026-03-13
PT4122926T (pt) 2025-07-29
ES3038833T3 (en) 2025-10-15
JPWO2022138987A1 (https=) 2022-06-30
EP4400502A2 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
CN115850249B (zh) 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物
BRPI0716918A2 (pt) Composto, composição farmacêutica, composição farmacêutica embalada, método de tratar um paciente que apresente uma doença responsiva à inibição da atividade btk, método de tratar um paciente que apresente uma doença escolhida dentre câncer, doenças autoimunes, reações inflamatórias agudas e transtornos alérgicos, método de aumentar a sensibilidade de células cancerosas à quimioterapia, método de reduzir o erro de medicação e melhorar o cumprimento terapêutico de um paciente sendo tratado para uma doença responsiva à inibição da atividade btk, método de inibir a hidrólise de atp, método para determinar a presença de btk em uma amostra, método de inibir a atividade de células-b
JP7624093B2 (ja) ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物
WO2023054292A1 (ja) トリアジン誘導体を含有する医薬組成物
WO2023042879A1 (ja) ウイルス増殖阻害活性を有する二環性複素環誘導体およびそれらを含有する医薬組成物
JP7236065B1 (ja) トリアジン誘導体を含有する医薬組成物
WO2023095860A1 (ja) ３ｃｌプロテアーゼ阻害剤及びｃｏｖｉｄ－１９治療用薬剤を組み合わせることを特徴とするｃｏｖｉｄ－１９治療用医薬
JP7261529B1 (ja) ウイルス増殖阻害作用を有するトリアジン誘導体の製造方法
CN116782904A (zh) 含有三嗪衍生物的医药组合物
JP2024512753A (ja) 新規なジアルコキシナフト［２，３－ｃ］フラン－１（３Ｈ）－オン誘導体およびこれを含む呼吸器疾患またはＳＡＲＳ－ＣｏＶ－２感染症の予防または治療用の薬学的組成物
US20260125365A1 (en) Triazine derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same
HK40081541A (en) Triazine derivative having virus propagation inhibitory effect, and pharmaceutical composition containing same
HK40081541B (zh) 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物
RU2806042C1 (ru) Триазиновые производные, имеющие ингибиторную активность в отношении репликации вируса, и содержащая их фармацевтическая композиция
CN117999257A (zh) 具有病毒增殖抑制活性的双环杂环衍生物及含有其的药物组合物
WO2025074997A1 (ja) ウイルス増殖阻害活性を有する縮合複素環誘導体およびそれらを含有する医薬組成物
JP2025114610A (ja) ウラシル誘導体の製造方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant